To include your compound in the COVID-19 Resource Center, submit it here.

Veletri tezosentan: Phase III

ATLN and partner Genentech Inc. (DNA, South San Francisco, Calif.) said that in a placebo-controlled Phase III trial

Read the full 184 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE